VP, Medical Affairs

MD (preferred), PhD, PharmD, or relevant advanced degree with 10+ years of experience in pharma or biotech drug development (preferred), or academia.

Demonstrated ability to build best-in-class medical capabilities.

Demonstrated ability to shape treatment landscapes through compelling medical strategies and plans.

Extensive knowledge of drug development and/or experience in more than one functional area such as clinical, med affairs, translational development, regulatory, commercial, safety, etc., to assure broad understanding of the pharmaceutical development.

Prior oncology or malignant hematology experience, particularly in multiple myeloma and/or prior cellular therapy experience is preferred.

Prior NDA, or BLA filing/submission & launch experience is a plus.

$338,656

—

$444,486 USD

Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech.

The VP of Medical Affairs is an essential role in the company with significant impact on the clinical understanding of Legend’s approved BCMA CAR-T for multiple myeloma, as well the development of pipeline programs.

The VP of Medical Affairs will provide strategic leadership to develop and execute an integrated Medical Affairs Strategy, working closely with collaboration partners, such as Johnson & Johnson, as well as partners within the company such as Commercial, Clinical Development, Translational Development, Safety, Regulatory, Healthcare Compliance and Legal.

Core responsibilities will encompass developing & executing medical affairs strategy and providing leadership and direction to the medical affairs team (home office and field-based) and executing on significant initiatives including scientific communications, publications, lifecycle planning, data generation, KOL engagement, and educational programming.

In addition, this leader will help build Medical Affairs capabilities to support our emerging pipeline.

This position reports to the President of the CARVYKTI business unit and is a member of the CARVYKTI leadership team, with close collaboration with the President of R&D.

Positively impact the educational and clinical needs of the multiple myeloma-treating community (and more broadly the hematology community) in understanding the role of BCMA CAR-T in the treatment landscape, including its use earlier in the treatment paradigm.

For information related to our privacy notice, please review:

Legend Biotech Privacy Notice

.